A group of proteins that modulate immune responses, called heat shock proteins (HSPs), are significantly elevated in the kidneys of people with ANCA-associated vasculitis (AAV), and their levels are associated with poorer kidney function and organ survival, a multi-year study found. These…
Heat Shock Proteins in Kidneys Linked to Poorer Outcomes in AAV Patients
Same But Different, a nonprofit U.K. group that uses art for social change, is inviting people to choose their favorite photographs in a calendar contest to heighten awareness of rare diseases, including amyotrophic lateral sclerosis (ALS). The organization’s panel of judges has pared the number of contest submissions…
I was in a hospital room, dazed and confused. A doctor had sent me there after a chaotic trip to the emergency room. The first nurse to treat me said I had a hemoglobin level of 3.8 deciliters. My resting heart rate was 140 beats per minute, and when I…
Adding plasma exchange to immune-suppressing treatment does not significantly improve clinical outcomes in people with ANCA-associated vasculitis (AAV), a new meta-analysis indicates. The analysis, “The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis,” was published in Clinical Rheumatology. AAV is characterized by…
My long journey began in Virginia in 2001 at 18. I was in college at the time, and two friends and I decided to go on a trip during a three-day weekend in the spring. We stayed at my friend’s house, and I remember very clearly getting a pain in…
High blood levels of FCRL5 — a protein mainly found in certain B-cells, a type of immune cell — are linked with a greater likelihood of achieving and maintaining a complete response to rituximab in people with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),…
Exagen, a life sciences company developing tests for the diagnosis, prognosis, and monitoring of autoimmune conditions, has launched a new test for the rapid diagnosis of ANCA-associated vasculitis (AAV). Named AVISE Vasculitis AAV, the test measures for a panel of biomarkers, each of which helps determine the…
The U.S. Food and Drug Administration (FDA) has accepted for review ChemoCentryx‘s application requesting the approval of avacopan to treat ANCA-associated vasculitis (AAV), the company announced in a press release. The agency expects to announce its decision regarding approval on or before July 7, 2021.
The 20S-proteasome — the core of an enzyme complex responsible for eliminating unnecessary or damaged proteins in cells — may be a useful biomarker of disease activity in people with ANCA-associated vasculitis (AAV), a study shows. The study, “Serum 20S proteasome levels are associated with…
ANCA-associated vasculitis (AAV) carries high healthcare costs for therapies and hospitalizations to treat the disease itself and related infections, a study in Italy has found. The study, “Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases,” was published…
Recent Posts
- New analysis identifies phase-specific relapse risks in AAV treatment
- Sharing with others about vasculitis can strengthen connections
- New nanoparticle approach targets kidney damage in vasculitis
- Study points to 2 biomarkers for AAV disease activity, relapse
- Monitoring our kidney health is crucial with ANCA vasculitis